Caladrius Biosciences to Participate in Upcoming January Conferences
January 07 2019 - 8:00AM
Caladrius Biosciences to Participate in Upcoming January
Conferences
BASKING RIDGE, N.J. (January 7, 2019) –
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company with multiple technology platforms targeting select
cardiovascular indications and autoimmune disease, announced today
that management will participate at the following conferences in
January:
Regenerative Medicine Crossroad in Tokyo #9
Presentation
Title:
Autologous CD34 cell therapy for critical limb ischemia: a
long-term Japanese-American partnershipDate &
Time:
Monday, January 28, 2019 at 2:50 p.m.
(JST)Presenter:
Douglas Losordo, M.D., FACC, FAHA, Executive Vice President, Global
Head of Research and Development, Chief Medical OfficerVenue:
Nihonbashi Life Science Building 2F in Tokyo, Japan
2nd Innovative Regulatory Pathways
SummitPresentation
Title:
Sakigake Designation System: A Japanese Strategy for Expedited Drug
DevelopmentDate &
Time:
Tuesday, January 29, 2019 at 9:30 a.m.
(EST)Presenter:
William K. Sietsema, Ph.D., Vice President, Global Regulatory
AffairsVenue:
Sheraton Pentagon City in Arlington, Virginia
About Caladrius Biosciences
Caladrius is a late-stage therapeutics development
biopharmaceutical company committed to the development of
innovative products that have the potential to restore the health
of people with chronic illnesses. Our leadership team collectively
has decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other
areas. The Company’s goal is to build a broad portfolio
of novel and versatile products that address important unmet
medical needs. Our current product candidates include three
developmental treatments for cardiovascular diseases based on our
CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE
designation, in Phase 2 testing in Japan and eligible for early
conditional approval for the treatment of critical limb ischemia;
CLBS14-CMD, in Phase 2 testing for the treatment of coronary
microvascular dysfunction and CLBS14-NORDA (formerly CLBS14-RfA) in
late-stage development for no option refractory disabling angina
for which it has received RMAT designation. Caladrius’ autoimmune
product candidate in Phase 2 testing, CLBS03, is an ex
vivo expanded polyclonal T regulatory cell therapy for the
treatment of recent-onset type 1 diabetes. CLBS03 has been awarded
Fast Track and Orphan designations by the FDA. For more
information on the company, please visit www.caladrius.com.
Contacts:
Caladrius Biosciences, Inc.John MendittoExecutive Director,
Investor Relations and Corporate CommunicationsPhone:
+1-908-842-0084Email: jmenditto@caladrius.com
# # #
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024